Download full-text PDF |
Source |
---|
Mod Pathol
January 2025
Interdisciplinary Oncology, University of British Columbia, Vancouver, BC, Canada; MAPcore, University of British Columbia, Vancouver, BC, Canada. Electronic address:
Assessment of the tumor immune microenvironment can be used as a prognostic tool for improved survival and as a predictive biomarker for treatment benefit, particularly from immune modulating treatments including cytotoxic chemotherapy. Using Digital Spatial Profiling (DSP), we studied the tumor immune microenvironment of 522 breast cancer cases by quantifying 35 immune biomarkers on tissue microarrays from the MA.5 phase III clinical trial.
View Article and Find Full Text PDFTissue Cell
December 2024
Department of Oral Medicine and Radiology, Faculty of Dental Sciences. King George's Medical University, Lucknow, India. Electronic address:
Background: The treatment of congenital deformities, traumatic injuries, infectious diseases, and tumors in the craniomaxillofacial (CMF) region is complex due to the intricate nature of the tissues involved. Conventional treatments such as bone grafts and cell transplantation face limitations, including the need for multiple surgeries, complications, and safety concerns.
Objective: This paper aims to provide a comprehensive analysis of the role of exosomes (EXOs) in CMF and dental tissue regeneration and to explore their potential applications in regenerative dental medicine.
J Clin Med
October 2024
Radiation Oncology Unit, Oncology Research Institute of Basilicata-IRCCS-CROB, 85028 Rionero in Vulture, PZ, Italy.
Hypertension
November 2024
Division of Precision Medicine, Department of Medicine, NYU Langone Health, New York (W.-J.Y., R.A., A.L.S., C.M.F., M.E.G.).
Background: The prevalence of hypertension and uncontrolled hypertension may differ by age and sex.
Methods: We included participants in the Atherosclerosis Risk in Communities study at seven study visits over 33 years (visit 1: 15 636 participants; mean age, 54 years; 55% women), estimating sex differences in prevalence of hypertension (systolic blood pressure ≥130 mm Hg; diastolic blood pressure ≥80 mm Hg; or self-reported antihypertension medication use) and uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) using unadjusted and comorbidity-adjusted models.
Results: The prevalence of hypertension increased with age from 40% (ages, 43-46 years) to 93% (ages, 91-94 years).
Biol Pharm Bull
August 2024
Department of Pharmaceutical Sciences, Suzuka University of Medical Science.
Research on sex differences has increased across various fields, including cancer and its treatment domains. Reports have indicated sex differences in cancer incidence, survival rates, and the efficacy of anticancer drugs. However, such reports are limited, and in-depth assessments of the underlying mechanisms are still in progress.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!